[Clinical studies on dibekacin for infectious diseases following intramuscular and intravenous drip administration. Concentration in infected tissues and clinical responses (author's transl)].
An antibiotic drug of aminoglycoside group, dibekacin (DKB) for parental use was used in 48 patients hospitalized due to acute or subacute infection of abdominal organs: 36 appendicitis, 9 cholecystitis and 3 others. DKB in a dose of 100 mg was given intramuscularly in 38 cases, and in 10 cases was given intravenously by single or drip infusion before the operation. The materials of A-bile, B-bile, wall of gallbladder, the appendix wall, ascites with pus and serum were taken during the operation. DKB concentration was measured by bioassay method with Bacillus Subtilis ATCC 6633 strain. With a few marked exceptions, DKB concentration in B-bile were higher than those in A-bile. DKB concentrations in gallbladder wall and appendix wall were directly proportional to the degree of pathological changes of inflammation. DKB concentrations in infected tissues after intravenous drip infusion, they were higher relatively than those after intramuscular administration. DKB concentrations in serum after intravenous drip infusion reached to peak immediately the end of infusion, and in the infected tissue they reached to peak at the same time and stayed for a relatively long time, then they were declined slowly. For the therapeutic purpose, DKB was given to the 6 patients with acute peritonitis of the above cases. DKB in a dose of 100 mg were administered by intravenous drip infusion for 2 hours, twice in a day for 3 - 10 days. Clinical response was excellent in 2 cases, good in 3 cases, fair in 1 case and poor in none. No adverse effect was observed. Therefore, it was supposed that DKB could be used safely by intravenous drip infusion.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000378:metabolism*; D001064:Appendicitis / Q000378:metabolism; D002648:Child; D002764:Cholecystitis / Q000378:metabolism; D003982:Dibekacin / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007273:Injections, Intramuscular; D007612:Kanamycin / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D010538:Peritonitis / Q000188:drug therapy; D014018:Tissue Distribution
D000900:Anti-Bacterial Agents; D003982:Dibekacin; D007612:Kanamycin